115754-65-9

Basic information

• Product Name: 4(3H)-Quinazolinone, 3-amino-6-bromo-2-phenyl-
• CAS NO: 115754-65-9
• Molecular Formula: C14H10BrN3O
• Molecular Weight: 316.157
• Mol File: 115754-65-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4(3H)-Quinazolinone, 3-amino-6-bromo-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(3H)-Quinazolinone, 3-amino-6-bromo-2-phenyl-(115754-65-9)
• EPA Substance Registry System: 4(3H)-Quinazolinone, 3-amino-6-bromo-2-phenyl-(115754-65-9)

Safety Data

• Hazardous Substances Data: 115754-65-9(Hazardous Substances Data)

Upstream product

• 857589-28-7 2-benzamido-5-bromobenzoic acid 
• 118-92-3 anthranilic acid 
• 66387-70-0 6-bromo-2-phenyl-4H-benzo[2,3-d]-1,3-oxazin-4-one 
• 98-88-4 benzoyl chloride 

Downstream Products

• 160008-39-9 6-bromo-2-phenyl-3-amino-4(3H)-quinazolinone 
• 1006594-95-1 C₁₉H₁₂BrN₃O₂ 
• 1006594-98-4 C₂₀H₁₄BrN₃O₂ 
• 1006595-07-8 C₁₉H₁₁BrN₄O₄ 
• 170299-18-0 6-bromo-2-phenyl-3-amino-4(3H)-quinazolinone 
• 160008-40-2 6-bromo-2-phenyl-3-amino-4(3H)-quinazolinone 
• 174759-01-4 6-bromo-2-phenyl-3-amino-4(3H)-quinazolinone 
• 171285-20-4 Acetic acid (2R,3R,4S,5S)-4,5-diacetoxy-2-[acetyl-(6-bromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)-amino]-tetrahydro-pyran-3-yl ester 
• 171285-18-0 Acetic acid (2R,3R,4R,5R)-4,5-diacetoxy-2-[acetyl-(6-bromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)-amino]-tetrahydro-pyran-3-yl ester 
• 171482-62-5 6-Bromo-2-phenyl-3-((2R,3R,4S,5S)-3,4,5-trihydroxy-tetrahydro-pyran-2-ylamino)-3H-quinazolin-4-one 

Relevant articles and documents

Quinazolinone platinum metal complexes: In silico design, synthesis and evaluation of anticancer activity

Dihydrofolate reductase (DHFR) has been explored as a target for the development of agents for wide variety of human diseases, including cancer, autoimmune and infectious diseases. Several metal complexes are being used in management of cancer. The square planar Pt(II) complex, cis PtCl2(NH3)2 turned out to be even more effective at forcing filamentous growth. Cisplatin is an inorganic heavy metal complex that has activity similar to cell-cycle-phase-nonspecific alkylating agents such as cyclophosphamide and some other Ni and Cu metal complexes. It produces intrastrand DNA cross-link and form DNA adducts, thus inhibiting the synthesis of DNA, RNA and proteins preferentially. in silico Screening of platinum metal complexes was performed by Vlife MDS 4.3 software. In this procedure, selection of molecule, selection of PDB, optimization of PDB and docking of molecules was carried out. Synthesis of metal complexes was done by multi component reaction method. Platinum metal complexes of quinazolinone Schiff bases prioritized by in silico studies were characterized by IR, TLC, NMR, XRD, FESEM and some physico-chemical parameters. Prioritized molecules were further evaluated by in vitro anticancer cell line assay on ten cell lines with adriamycin as standard. The results showed that the platinum metal complexes of qunazolinone Schiff bases can be potential anticancer agents through DHFR inhibitory mechanism.

Synthesis and antiviral activity of 2-aryl-3-(substituted-benzalamino)- 4(3H)-quinazolinones

A series of new heterocyclic compounds 2-aryl-3-(substituted-benzalamino)- 4(3H)-quinazolinone have been synthesized by the treatment of 3-amino-2-aryl-4(3H)-quinazolinone with a substituted benzaldehyde in ethanol. All the synthesized compounds were char

Synthesis of some new aziridine derivatives

Oxidation of 3-amino-6-bromo-2-phenylquinazolin4(3H)-one (2) with lead tetraacetate at - 20°C gives 3-acetoxyamino-6-bromo-2-phenylquinazolin-4( 3 H )-one (3) which selectively aziridinates the olefinic esters to yield methyl/ethyl 1 -[6-bromo-4(3H)-oxo-2